G-CSF（顆粒細胞增生因子）市場報告：2031 年趨勢、預測與競爭分析

全球 G-CSF（顆粒細胞增生因子）市場前景光明，在腫瘤疾病、血液疾病、生長激素缺乏症、慢性疾病和自體免疫疾病市場都存在機會。預計到 2031 年，全球 G-CSF（顆粒細胞增生因子）市場規模將達到 107 億美元，2025 年至 2031 年的複合年成長率為 3.2%。該市場的主要驅動力是癌症發病率的上升和醫療保健成本的上升。

• Lucintel 預測膠囊在預測期內將出現高速成長。
• 根據應用，腫瘤學預計將實現最高成長。
• 根據地區，預計北美將在預測期內實現最高成長。

G-CSF（顆粒細胞增生因子）市場的策略性成長機會

G-CSF（顆粒細胞增生因子）市場呈現多種策略成長機會。以下五點似乎是最重要的：

• 多樣化的市場成長：隨著醫療保健系統的改善，癌症發生率不斷上升，靶向 G-CSF 製劑可能會在新興國家顯著成長。在這些地區引入生物相似藥將增加市場進入和收益。
• 聯合治療的開發：將 G-CSF 與其他抗癌藥物結合，可以實現 G-CSF 的最佳劑量。這項策略將有利於尋求解決嗜中性白血球低下症的醫療保健專業人員，因為單獨使用 G-CSF 往往是不夠的。
• 研發投資：進一步的研發投資可能會帶來新的先進 G-CSF 配方的開發。這種方法可以幫助滿足不斷變化的患者需求並提高依從性。
• 夥伴關係和協作：與生物技術公司和研究機構建立策略聯盟有助於有效開發新型 G-CSF 配方。透過採用尖端技術和新理念，您可以加強行銷策略並刺激市場成長。
• 利用數位健康工具：在 G-CSF 治療管理中利用數位健康策略可能會改善治療結果。此外，針對慢性病管理客製化的遠端醫療和行動應用程式可以幫助提高依從性並增強治療效果。

這些策略性成長機會可以透過增加治療的​​可用性、刺激新方法和改善患者醫療保健計劃來促進 G-CSF（顆粒細胞增生因子）市場的發展。因此，對於 G-CSF 領域的市場參與企業來說，為了在這個競爭激烈的市場中取得成功，這些趨勢至關重要。

G-CSF（顆粒細胞增生因子）市場促進因素與挑戰

G-CSF（顆粒細胞增生因子）市場的成長受到多種促進因素​​和挑戰的顯著影響。這些因素對於希望在這個市場上運作的相關人員來說至關重要。

推動 G-CSF（顆粒細胞增生因子）市場的因素有：

• 癌症發生率上升：G-CSF（顆粒細胞增生因子）市場分化的主要原因是癌症人口的增加，這增加了對 G-CSF 療法（例如針對化療引起的嗜中性白血球低下症的療法）的市場。隨著癌症發生率的上升，透過使用有效的檢測方法為患者提供適當的護理已成為當務之急。
• 生物技術的進步：生物技術領域正在進行許多創新，以開發新型 G-CSF 配方。隨著新配方和給藥途徑的改變使治療更加有效並鼓勵更多患者繼續治療，市場正在擴大。
• 提高對嗜中性白血球低下症管理的認知：醫療保健專業人員和患者對管理嗜中性白血球低下症的必要性的認知不斷提高，從而增加了 G-CSF 的使用。現在，我們對患者進行了有關該疾病的教育，並且患者在早期階段就尋求幫助，從而獲得了更好的治療效果。
• 支持性法律規範：監管機構正在積極主動地與公司合作，以生產和獲得新的 G-CSF 產品的核准。這種支持將加速新治療方法的市場推廣。
• 生物相似藥創新：隨著生物相似藥在 G-CSF（顆粒細胞增生因子）市場中不斷獲得佔有率，競爭將會加劇，價格將會下降。這將使患者更容易接受 G-CSF 治療，進而導致 G-CSF 治療的快速普及。

G-CSF（顆粒細胞增生因子）市場的挑戰如下：

• 開發成本高：開發和商業化 G-CSF 產品需要大量資金，這可能會阻礙進一步的投資和創新。在這樣一個資本密集的行業中，這可能會對新參與企業造成阻礙。
• 市場飽和：學名藥和生物相似藥的激增可能導致市場飽和，使差異化變得困難。為了在這種競爭環境中生存，公司需要積極主動地採用創新。
• 監管障礙：試圖進入市場的新型 G-CSF 產品可能會因監管流程的複雜性而受到阻礙。嚴格的安全和功效法規可能會延遲產品上市並增加開發成本。

G-CSF（顆粒細胞增生因子）市場的趨勢受到癌症發生率上升、生物技術進步和生物相似藥擴張等因素的影響。然而，高昂的開發成本、市場飽和和複雜的法規等挑戰可能會限制成長和創新。該地區的相關人員需要在利用市場驅動力的同時應對這些挑戰。這些力量預計將影響 G-CSF（顆粒細胞增生因子）市場的供需平衡。

目錄

第1章執行摘要

2. 全球顆粒細胞增生因子(G-CSF) 市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章 2019年至2031年市場趨勢及預測分析

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球G-CSF（顆粒細胞增生因子）市場趨勢（2019-2024年）及預測（2025-2031年）
• 按類型：G-CSF（顆粒細胞增生因子）市場
  • 膠囊
  • 錠劑
  • 其他
• 全球G-CSF（顆粒細胞增生因子）市場應用狀況
  • 腫瘤疾病
  • 血液系統疾病
  • 生長激素缺乏症
  • 慢性及自體免疫疾病
  • 其他

第4章2019年至2031年區域市場趨勢與預測分析

• 按地區：G-CSF（顆粒細胞增生因子）市場
• 北美G-CSF（顆粒細胞增生因子）市場
• 歐洲G-CSF（顆粒細胞增生因子）市場
• 亞太顆粒細胞增生因子（G-CSF）市場
• 世界其他地區G-CSF（顆粒細胞增生因子）市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按類型：全球 G-CSF（顆粒細胞增生因子）市場的成長機會
  • 按應用：全球G-CSF（顆粒細胞增生因子）市場的成長機會
  • 按地區：全球 G-CSF（顆粒細胞增生因子）市場的成長機會
• 全球G-CSF（顆粒細胞增生因子）市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球G-CSF（顆粒細胞增生因子）市場容量不斷擴大
  • 全球G-CSF（顆粒細胞增生因子）市場的合併、收購及合資企業
  • 認證和許可

第7章主要企業簡介

• Amgen
• Coherus Biosciences
• Sandoz
• Biocon/Mylan
• Teva Pharmaceuticals
• Chugai Pharma
• Intalfarmaco
• Pfizer
• Sun Pharmaceutical Industries
• BeyondSpring

The future of the global G-CSF (granulocyte colony stimulating factor) market looks promising with opportunities in the oncological disease, blood disorder, growth hormone deficiencies, and chronic and autoimmune disorder markets. The global G-CSF (granulocyte colony stimulating factor) market is expected to reach an estimated $10.7 billion by 2031 with a CAGR of 3.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cancer and rise in healthcare expenses.

• Lucintel forecasts that, within the type category, the capsule is expected to witness higher growth over the forecast period.
• Within the application category, oncological disease is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the G-CSF (Granulocyte Colony Stimulating Factor) Market

Numerous changes are being witnessed in the G-CSF (granulocyte colony stimulating factor) market, and these changes will help revolutionize the treatment model and market landscape. Five such trends are summarized below.

• Increased Focus on Biosimilars: Competition in the G-CSF (granulocyte colony stimulating factor) market is being enhanced by the rise of biosimilars, resulting in lower prices and higher patient rates. With a couple of biosimilars already on the market, it is easier for healthcare providers to manage patients appropriately, which enhances adherence to treatment and improves overall health.
• Personalized Medicine Approaches: A growing trend in personalized medicine is also affecting G-CSFs. Different patients presenting the same symptoms may have unique biological factors that should be considered. Therefore, the development of these new therapies becomes more targeted while limiting toxicity and enhancing the quality of life for patients.
• Innovative Delivery Methods: New drug delivery systems, such as long-acting formulations and delivery via subcutaneous injection, are being introduced to increase compliance. These innovations also reduce the frequency of treatment, which is especially helpful for patients undergoing chemotherapy.
• Regulatory Support and Guidance: Fundamental changes in medicine and health practices have led to regulations stipulating the use and administration of G-CSFs, enhancing care. Various guidelines also encourage monitoring, which is important in standardizing treatment practices among healthcare providers and ensuring that the necessary skills are available to treat patients optimally.
• Integration of Digital Health Solutions: Digital health technologies, including telehealth and mobile applications for health management, are being adopted to assist in patient care during G-CSF therapy. These tools help improve patient adherence and control side effects through enhanced interactions with healthcare providers.

These trends are altering the G-CSF (granulocyte colony stimulating factor) market by spurring creativity, increasing the number of patients who can be treated, and improving treatment outcomes. To deliver patient care effectively in this expanding market, these factors will be crucial in determining and developing future therapeutic approaches.

Recent Developments in the G-CSF (Granulocyte Colony Stimulating Factor) Market

Within the G-CSF (granulocyte colony stimulating factor) market, there have been remarkable developments that address therapeutic efficacy and treatment parameters. Below are several noteworthy advancements in this field.

• Launch of New Biosimilars: The entry of several biosimilars has resulted in fierce competition in the G-CSF (granulocyte colony stimulating factor) market, which has led to reduced prices and increased market penetration. This enables providers to offer more treatment options to patients without sacrificing quality.
• Advancements in Long-Acting Formulations: Novel long-acting G-CSF formulations are gaining traction, requiring administration at longer intervals. These modifications increase patient compliance, especially for those undergoing chemotherapy, improving convenience and adherence rates.
• Integration of Telehealth Solutions: Patients undergoing G-CSF therapy benefit from remote monitoring and consultations through telehealth platforms. This promotes patient participation and facilitates the timely enhancement of care.
• Clinical Trials for New Indications: New trials are investigating the use of G-CSF for patients with severe infections or autoimmune diseases. The expanded application of G-CSF could address unmet medical needs in various patient populations.
• Regulatory Approvals for Combination Therapies: New application regions for G-CSF have approved combination therapy protocols, suggesting that consolidating treatment strategies could improve outcomes, particularly in complicated clinical situations, and provide clinicians with a wider range of treatment options.

These changes are contributing to positive developments in the G-CSF (granulocyte colony stimulating factor) market, enhancing treatment accessibility, improving patient adherence, and broadening treatment options. As these trends continue, they will play an increasingly important role in shaping the future of the G-CSF (granulocyte colony stimulating factor) market.

Strategic Growth Opportunities for G-CSF (Granulocyte Colony Stimulating Factor) Market

The G-CSF (granulocyte colony stimulating factor) market presents several strategic growth opportunities. The following five appear to be the most critical.

• Diverse Market Growth: Targeted G-CSF products are likely to experience significant growth in developing countries, where cancer incidence is rising alongside improvements in healthcare systems. The introduction of biosimilars in these regions will increase market access and revenue.
• Development of Combination Therapies: The optimal administration of G-CSF can be achieved by combining it with other oncological drugs. This strategy will benefit healthcare professionals seeking solutions for neutropenia, which often requires more than just G-CSF administration.
• Investment in Research and Development: Further investment in R&D could lead to the development of new and advanced G-CSF products. This approach will address the changing needs of patients and improve compliance.
• Partnerships and Collaborations: Strategic collaborations with biotech companies and research organizations will help efficiently develop novel G-CSF products. Shared efforts can enhance marketing strategies by incorporating cutting-edge technologies and new ideas, spurring market growth.
• Utilization of Digital Health Tools: The use of digital health strategies in managing G-CSF therapy is likely to improve therapeutic outcomes. Telemedicine and mobile applications tailored for chronic illness management will also help improve compliance and enhance the effectiveness of treatment.

These strategic growth opportunities can boost the G-CSF (granulocyte colony stimulating factor) market by increasing treatment availability, stimulating new approaches, and improving healthcare planning for patients. Therefore, these trends are essential for market participants in the G-CSF sector to consider for success in this competitive market.

G-CSF (Granulocyte Colony Stimulating Factor) Market Driver and Challenges

The growth of G-CSF (granulocyte colony stimulating factor) market is largely affected by numerous drivers and most of the challenges. These factors are very critical to the stakeholders who wish to operate in this market.

The factors responsible for driving the G-CSF(granulocyte colony stimulating factor) market include:

• Rising Cancer Incidence: The main source of differentiation for G-CSF (granulocyte colony stimulating factor) market is the increasing cancer population which increases the market of the G-CSF therapies such as the ones targeting chemotherapy-induced neutropenia. Because of the rising incidences of cancer, the focus on providing proper care to the patients through the use of effective assays is becoming essential.
• Advancements in Biotechnology: There are many technological innovations in the biotechnology field for the development of novel G-CSF products. New formulations and change in the routes of administration make treatments more effective and more patients adhere to therapy thus widening the market.
• Growing Awareness of Neutropenia Management: There is an increase in the healthcare providers' and Zulfiqar Ahmed patients' appreciation regarding the need to manage neutropenia thereby increasing the use of G-CSF. Education is upon patients in relation to the disease which encourages them to seek help very early on thus getting better results.
• Supportive Regulatory Frameworks: Regulatory bodies are in contact with firms either prospectively or retrospectively encouraging them to undertake processes of making new G-CSF products and getting them approved- this validates and creates a desideratum for development. This support expedites the introduction into the market of new medicinal treatments.
• Innovation of Biosimilars: As biosimilar products continue to gain a larger share in the G-CSF (granulocyte colony stimulating factor) market, competition heats up and prices decline. This makes it easier for patients to undergo G-CSF which in turn brings about the fast uptake of G-CSF therapy methods into practice.

Challenges in the G-CSF (granulocyte colony stimulating factor) market are:

• High Development Costs: Developing and commercializing a G-CSF product is capital-intensive, which may discourage further investment and innovation. In such a capital-heavy industry, this may deter new market players.
• Market Saturation: The proliferation of generics and biosimilars may lead to market saturation, where differentiation becomes difficult. Organizations must actively introduce innovations to survive in this competitive environment.
• Regulatory Hurdles: The complexity of regulatory processes sometimes interferes with the ability of companies to launch new G-CSF products. Strict safety and efficacy regulations may delay product availability in the market and inflate development costs.

The G-CSF (granulocyte colony stimulating factor) market trends are influenced by factors such as increasing cancer incidences, technological advances in biotechnology, and the growing range of biosimilars. However, issues like high development costs, market saturation, and complex regulations could limit growth and innovation. Stakeholders in the region will need to address these challenges while capitalizing on market drivers. These forces will shape the balance between supply and demand in the G-CSF (granulocyte colony stimulating factor) market.

List of G-CSF (Granulocyte Colony Stimulating Factor) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies G-CSF (granulocyte colony stimulating factor) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the G-CSF (granulocyte colony stimulating factor) companies profiled in this report include-

• Amgen
• Coherus Biosciences
• Sandoz
• Biocon/Mylan
• Teva Pharmaceuticals
• Chugai Pharma
• Intalfarmaco
• Pfizer
• Sun Pharmaceutical Industries
• BeyondSpring

G-CSF (Granulocyte Colony Stimulating Factor) by Segment

The study includes a forecast for the global G-CSF (granulocyte colony stimulating factor) market by type, application, and region.

G-CSF (Granulocyte Colony Stimulating Factor) Market by Type [Analysis by Value from 2019 to 2031]:

• Capsule
• Tablet
• Others

G-CSF (Granulocyte Colony Stimulating Factor) Market by Application [Analysis by Value from 2019 to 2031]:

• Oncological Disease
• Blood Disorder
• Growth Hormone Deficiencies
• Chronic and Autoimmune Disorder
• Others

G-CSF (Granulocyte Colony Stimulating Factor) Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the G-CSF (Granulocyte Colony Stimulating Factor) Market

The Granulocyte Colony Stimulating Factor (G-CSF) market is expected to grow rapidly due to factors such as advancements in biotechnology, increasing awareness of neutropenia management, and the rising demand for cancer therapeutics. G-CSF plays a crucial role in boosting neutrophil counts, which is vital for chemotherapy patients and those suffering from various blood diseases. Drug formulation innovations and regulatory improvements in countries like the USA, China, Germany, India, and Japan are enhancing patient care and treatment outcomes.

• USA: G-CSF formulations such as pegfilgrastim have found widespread use in the U.S. among oncology patients due to the rise in chemotherapy-induced neutropenia. Several G-CSF biosimilars have been approved by the FDA, increasing market competition and availability. Recent clinical trials are exploring new methods of administration, including subcutaneous injections, to improve patient convenience. Additionally, there is a growing focus on individualized treatment plans that enhance the effectiveness of G-CSF therapies.
• China: The G-CSF (granulocyte colony stimulating factor) market in China is expanding rapidly due to the increasing number of cancer patients and the aging population. To support the research and manufacturing of G-CSF drugs, the government has implemented favorable policies, leading to an increase in the number of new biosimilars on the market. New strategies have been introduced to ensure the safe use of G-CSF in cancer patients, while local pharmaceutical companies are collaborating with global biotech firms to improve product access.
• Germany: Germany is making significant strides in G-CSF therapies, with ongoing efforts to develop advanced delivery systems and formulations. Recent studies focus on improving treatment plans to achieve the desired outcomes while minimizing toxicity. The country has also seen a rise in biosimilar development, which is likely to improve access to treatment and lower costs for patients. Regulatory bodies are actively advocating for best practices in G-CSF use, helping standardize care for oncology patients.
• India: The G-CSF (granulocyte colony stimulating factor) market in India is growing due to the increasing incidence of cancer and improved healthcare access. Neutropenic patients now have more treatment options as affordable G-CSF biosimilars become available. Campaigns to raise awareness of chemotherapy side effect management among healthcare providers are gaining traction. Additionally, efforts by Indian pharmaceutical companies, along with potential collaborations with international organizations, are accelerating the development of novel G-CSF formulations.
• Japan: Japan's G-CSF (granulocyte colony stimulating factor) market is focused on drug development with the support of advanced technologies. New long-acting G-CSF formulations that require less frequent administration are improving patient adherence to treatment. Additionally, the regulatory environment is becoming more favorable for biosimilars, speeding up their approval process. Clinical studies are increasingly focused on tailoring G-CSF therapy to specific patient conditions, which is expected to enhance treatment efficacy for cancer patients.

Features of the Global G-CSF (Granulocyte Colony Stimulating Factor) Market

Market Size Estimates: G-CSF (granulocyte colony stimulating factor) market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: G-CSF (granulocyte colony stimulating factor) market size by type, application, and region in terms of value ($B).

Regional Analysis: G-CSF (granulocyte colony stimulating factor) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the G-CSF (granulocyte colony stimulating factor) market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the G-CSF (granulocyte colony stimulating factor) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the G-CSF (granulocyte colony stimulating factor) market by type (capsule, tablet, and others), application (oncological disease, blood disorder, growth hormone deficiencies, chronic and autoimmune disorder, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global G-CSF (Granulocyte Colony Stimulating Factor) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global G-CSF (Granulocyte Colony Stimulating Factor) Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Type
  • 3.3.1: Capsule
  • 3.3.2: Tablet
  • 3.3.3: Others
• 3.4: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Application
  • 3.4.1: Oncological Disease
  • 3.4.2: Blood Disorder
  • 3.4.3: Growth Hormone Deficiencies
  • 3.4.4: Chronic and Autoimmune Disorder
  • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Region
• 4.2: North American G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.2.1: North American Market by Type: Capsule, Tablet, and Others
  • 4.2.2: North American Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.3: European G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.3.1: European Market by Type: Capsule, Tablet, and Others
  • 4.3.2: European Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.4: APAC G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.4.1: APAC Market by Type: Capsule, Tablet, and Others
  • 4.4.2: APAC Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others
• 4.5: ROW G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 4.5.1: ROW Market by Type: Capsule, Tablet, and Others
  • 4.5.2: ROW Market by Application: Oncological Disease, Blood Disorder, Growth Hormone Deficiencies, Chronic and Autoimmune Disorder, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Type
  • 6.1.2: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Application
  • 6.1.3: Growth Opportunities for the Global G-CSF (Granulocyte Colony Stimulating Factor) Market by Region
• 6.2: Emerging Trends in the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global G-CSF (Granulocyte Colony Stimulating Factor) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Amgen
• 7.2: Coherus Biosciences
• 7.3: Sandoz
• 7.4: Biocon/Mylan
• 7.5: Teva Pharmaceuticals
• 7.6: Chugai Pharma
• 7.7: Intalfarmaco
• 7.8: Pfizer
• 7.9: Sun Pharmaceutical Industries
• 7.10: BeyondSpring